On Jul. 21, 2021, Sorrento Therapeutics announced that COVID-19 patients had been dosed in its Phase 2 efficacy trial. Approximately 350 outpatients with COVID-19 who were asymptomatic or have mild symptoms were to be enrolled in this large double-blind, randomized clinical trial evaluating COVIDROPS doses of 10 mg or 20 mg against placebo.

This study used a novel decentralized design where subjects were assessed and treated in their homes and received a rapid review and clearance from the Medicines and Healthcare products Regulatory Agency in the UK.